Last $477.33 MXN
Change Today +14.53 / 3.14%
Volume 533.0
ABT* On Other Exchanges
Symbol
Exchange
New York
Mexico
London
Frankfurt
SIX Swiss Ex
As of 4:08 PM 06/17/13 All times are local (Market data is delayed by at least 15 minutes).

abbott laboratories (ABT*) Snapshot

Open
$477.33
Previous Close
$462.80
Day High
$477.33
Day Low
$477.33
52 Week High
05/28/13 - $482.72
52 Week Low
11/20/12 - $393.21
Market Cap
--
Average Volume 10 Days
632.3
EPS TTM
--
Shares Outstanding
0.0
EX-Date
07/11/13
P/E TM
--
Dividend
$0.56
Dividend Yield
3.53%
Current Stock Chart for ABBOTT LABORATORIES (ABT*)

Related News

No related news articles were found.

abbott laboratories (ABT*) Details

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. Its Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, pain, fever, inflammation, hypothyroidism, gynecological disorders, intrahepatic cholestasis or depressive symptoms, physiological rhythm of the colon, dyslipidemia, and hypertension, as well as provides anti-infective and influenza vaccines. The company’s Diagnostic Products segment provides diagnostic systems and tests, such as immunoassay and clinical chemistry systems; assays for screening and diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, and physiological and infectious diseases; genomic-based tests; hematology systems and reagents; and diagnostic systems and tests for blood analysis, as well as instruments that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents. Its Nutritional Products segment offers pediatric and adult nutritional products comprising various forms of prepared infant and follow-on formula. The company’s Vascular Products segment provides coronary, endovascular, vessel closure, and structural heart devices for the treatment of vascular disease. Abbott Laboratories also offers blood glucose monitoring meters, test strips, and data management software and accessories for people with diabetes; and medical devices for the eye, including cataract surgery, LASIK surgery, contact lens care products, and dry eye products. The company primarily serves retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices, and government agencies. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.

91,000 Employees
Last Reported Date: 03/27/13
Founded in 1888

abbott laboratories (ABT*) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.9M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $2.1M
Compensation as of Fiscal Year 2012.

abbott laboratories (ABT*) Key Developments

Abbott Declares Quarterly Dividend, Payable on August 15, 2013

The board of Abbott declared a quarterly common dividend of 14 cents per share. The cash dividend is payable August 15, 2013, to shareholders of record at the close of business on July 15, 2013.

Abbott Laboratories Initiates Randomized Clinical Trial in Japan to Evaluate the Absorb(TM) Bioresorbable Vascular Scaffold

Abbott Laboratories announced that it has initiated the ABSORB Japan randomized controlled clinical trial to evaluate the Absorb(TM) Bioresorbable Vascular Scaffold (BVS) in patients with coronary artery disease (CAD), the most common form of heart disease. The results of this trial will support regulatory filings with the Japanese Pharmaceutical and Medical Devices Agency (PMDA) for approval of Absorb BVS in Japan. The Absorb BVS, a drug eluting, fully bioresorbable vascular scaffold, is a small mesh tube designed to open a blocked heart vessel, restore blood flow to the heart and then dissolve into the vessel over time. Unlike a metallic stent that remains permanently in the body, Absorb is referred to as a scaffold to indicate that it is a temporary structure. Abbott's Absorb is made of polylactide, a naturally dissolvable material that is commonly used in medical implants such as dissolving sutures. CAD is the leading cause of death in the world. In Japan, changes in diet and lifestyle have raised concerns of a potential increase in heart disease-related deaths. According to the World Health Organization (WHO), cardiovascular disease is responsible for nearly one-third of all deaths in Japan.

Abbott Laboratories Presents at William Blair & Company 33(rd) Annual Growth Stock Conference, Jun-11-2013 11:30 AM

Abbott Laboratories Presents at William Blair & Company 33(rd) Annual Growth Stock Conference, Jun-11-2013 11:30 AM. Venue: Four Seasons Hotel, Chicago, Illinois, United States. Speakers: Brian Yoor, vice president, investor relations, David A. Forrest, Executive Vice President of Nutritional Products.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABT*:MM $477.33 MXN +14.53

ABT* Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 3,247 GBp +7.00
Bayer AG €83.27 EUR -0.13
Eli Lilly & Co $52.36 USD +0.31
Koninklijke Philips NV €21.71 EUR +0.52
Medtronic Inc $53.51 USD +0.59
View Industry Companies
 

Industry Analysis

ABT*

Industry Average

Valuation ABT* Industry Range
Price/Earnings 9.6x
Price/Sales 1.4x
Price/Book 2.5x
Price/Cash Flow 10.9x
TEV/Sales 1.0x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABBOTT LABORATORIES, please visit www.abbott.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.